Receptor imaging with 111In-pentreotide and 123I-methoxybenzamide, and inhibition tests with octreotide and bromocriptine of mixed growth hormone/prolactin-secreting pituitary tumors

Biomedicine and Pharmacotherapy

Volumn 53, Issue 7, 1999, Pages 319-322

  Panza, N ^a   Rambaldi, P F ^b   Battista, C ^a   Ambrosio, G ^c   Cascini, G L ^b   Schilliro F ^b   Mansi, L ^b  

^a Department of Onco Haematology ^*  (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c CARDARELLI HOSPITAL   (Italy)

Author keywords

Bromocruptine; IBZM; Octreotide; Pituitary tumors

Indexed keywords

BROMOCRIPTINE; GROWTH HORMONE; METHOXYBENZAMIDE IODINE I 123; OCTREOTIDE; PENTREOTIDE INDIUM IN 111; PROLACTIN; RADIOISOTOPE; UNCLASSIFIED DRUG; 3 IODO 2 HYDROXY 6 METHOXY N ((1 ETHYL 2 PYRROLIDINYL)METHYL)BENZAMIDE; 3-IODO-2-HYDROXY-6-METHOXY-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)BENZAMIDE; BENZAMIDE DERIVATIVE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; INDIUM; PYRROLIDINE DERIVATIVE; RADIOACTIVE IODINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; FOLLOW UP; GROWTH HORMONE RELEASE; HORMONE INHIBITION; HUMAN; HYPOPHYSIS TUMOR; MALE; PRIORITY JOURNAL; PROLACTIN RELEASE; TREATMENT OUTCOME; TUMOR VOLUME; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; SCINTISCANNING; SECRETION; TOMOGRAPHY;

ADULT; BENZAMIDES; BROMOCRIPTINE; CONTRAST MEDIA; GROWTH HORMONE; HUMANS; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OCTREOTIDE; PITUITARY NEOPLASMS; PROLACTIN; PYRROLIDINES; TOMOGRAPHY;

EID: 0033177921     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(00)88504-2     Document Type: Article

References (13)

1. Kojima Y, Arita J, Kuwana N, Kimura F. Dopamine responsiveness of human prolactinoma cells as determined by the reverse hemolytic plaque assay. Endocr J 1995; 42: 355-60.
2. Reubi JC, Randolt AM. The growth hormone response to octreotide in acromegaly correlates with adenoma somatostatin receptor status. J Clin Endocrinol Metab 1989; 68: 844-50.
3. 3]-octreotide: The Rotterdam experience with more than 1,000 patients. Eur J Nucl Med 1993; 20: 716-31.
4. Oppizzi G, Cozzi R, Dallabonzana D, Orlandi P, Benini Z, Petroncini M, et al. Scinigraphic imaging of pituitary adenomas: An in vivo evaluation of somatostatin receptors. J Endocrinol Invest 1998; 21: 512-9.
5. Scillitani A, Dicembrino F, Di Fazio P, Vettori PP, D' Angelo V, Scarabino T, et al. In vivo visualization of pituitary receptors by iodine-123-metoxybenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas. J Clin Endocrinol Metab 1995; 80: 2523-5.
6. 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas. J Clin Endocrinol Metab 1998; 83: 248-52.
7. Verhoeff NPLG, Bemelman FJ, Wiersinga WM, van Royen EA. Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with a TSH/PRL producing pituitary macroadenoma. Eur J Nucl Med 1993; 20: 555-61.
8. Bevan JS, Webster J, Burke CW, Scanion MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992; 13: 220-40.
9. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M. Recent advances in pathology, diagnosis and management of acromegaly. J Clin Endocrinol Metab 1995; 80: 3395-402.
10. Stewart PM, Kane KF, Stewart SE, Lacanjan I, Sheppard MC. Depot long-acting somatostatin analog (sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 1995; 80: 3267-72.
11. Colao A, Merola B, Ferone D, Marzullo P, Cerbone G, Longobardi S, et al. Acute and chronic effect of octreotide on thyroid axis in growth hormone-secreting and clinically nonfunctioning pituitary adenomas. Eur J Endocrinol 1995; 133: 189-94.
12. Plöckinger V, Reichel M, Fett V, Saeger W, Quabbe H.J. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: Effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 1994; 79: 1416-23.
13. Plöckinger U, Bader M, Hopfenmuller W, Saeger W, Quabbe HJ. Results of somatostatin receptor scintigraphy do not predict tumor volume and hormone response to octreotide therapy and do not correlate with tumor histology. Eur J Endocrinol 1997; 136: 369-76.